Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a/b study of DDY391 in Sjogren's syndrome
MOH_2026-06-21_016885Phase 2Recruiting
- Sponsor
- Novartis
- Start
- Jun 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of DDY391 in Sjögren's syndrome (8 arms), sponsored by Novartis. Primary endpoint: Change from baseline in ESSPRI at Week 24 versus placebo. Started Jun 2026; status: recruiting.
02
Drugs
DDY391
03
Conditions
Sjögren's syndrome
Beyond the preview
Go deeper on MOH_2026-06-21_016885.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2026-06-21_016885.